BOTHELL — ICOS Corp. continued to lose money during the past three months, a consequence of late-stage drug trials.
The third-quarter loss amounted to $21.7 million, or 47 cents a share, the company reported Thursday. That compares to a loss of $16.4 million, or 37 cents a share, during the comparable period last year.
The biotechnology firm, which has yet to reach the commercial market, is developing several drugs, including one for male impotence.
In a move that will increase revenue for the company while it develops those drugs, ICOS announced Thursday that it has signed an agreement with Seattle Genetics to do cell culture work for the Seattle company in ICOS labs.
Talk to us
- You can tell us about news and ask us about our journalism by emailing email@example.com or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to firstname.lastname@example.org or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.